Immuneering (IMRX) Profit After Tax (2020 - 2023)
Historic Profit After Tax for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$15.1 million.
- Immuneering's Profit After Tax fell 1387.58% to -$15.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$53.5 million, marking a year-over-year decrease of 585.6%. This contributed to the annual value of -$53.5 million for FY2023, which is 585.6% down from last year.
- Latest data reveals that Immuneering reported Profit After Tax of -$15.1 million as of Q4 2023, which was down 1387.58% from -$12.6 million recorded in Q3 2023.
- Over the past 5 years, Immuneering's Profit After Tax peaked at -$3.6 million during Q2 2020, and registered a low of -$15.1 million during Q4 2023.
- For the 4-year period, Immuneering's Profit After Tax averaged around -$10.1 million, with its median value being -$11.5 million (2022).
- As far as peak fluctuations go, Immuneering's Profit After Tax plummeted by 12162.34% in 2021, and later soared by 193.95% in 2023.
- Immuneering's Profit After Tax (Quarter) stood at -$5.8 million in 2020, then tumbled by 84.79% to -$10.8 million in 2021, then dropped by 22.82% to -$13.2 million in 2022, then decreased by 13.88% to -$15.1 million in 2023.
- Its Profit After Tax stands at -$15.1 million for Q4 2023, versus -$12.6 million for Q3 2023 and -$12.2 million for Q2 2023.